Suppr超能文献

选择性肿瘤DNA合成抑制:外源性酶介导的体内前药激活

Selective tumor DNA synthesis inhibition: in vivo prodrug activation by an exogenous enzyme.

作者信息

Tschiersch B, Schwabe K, Sydow G, Graffi A

出版信息

Cancer Treat Rep. 1977 Nov;61(8):1489-93.

PMID:21745
Abstract

Using the combination of alpha-L-arabinofuranosidase from Aspergillus niger with beta-peltatin A-alpha-L-arabinofuranoside, the selective effect of a new cancer of chemotherapy method based on a pH-dependent activation of cancerostatic prodrugs by exogenous enzymes was studied. In comparative experiments the selectivity of prodrug activation was measured by 3H-thymidine incorporation in tumor and normal tissues of CBA mice inoculated im with the transplantable mammary carcinoma, MA-21224. The results show that this special type of carrier principle may lead to a higher degree of selectivity than the usual direct application of cancerostatic drugs.

摘要

利用黑曲霉的α-L-阿拉伯呋喃糖苷酶与β-盾叶鬼臼毒素α-L-阿拉伯呋喃糖苷的组合,研究了一种基于外源性酶对抑癌前药的pH依赖性激活的新型癌症化疗方法的选择性作用。在对比实验中,通过将3H-胸腺嘧啶掺入接种了可移植性乳腺癌MA-21224的CBA小鼠的肿瘤和正常组织中,来测定前药激活的选择性。结果表明,这种特殊类型的载体原理可能比通常直接应用抑癌药物具有更高的选择性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验